Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (2807)	8/20/2003 9:55:42 AM
From: ACAN	Read Replies (2) \| Respond to of 23958

Godot; MPET - there must be something contrarian in MPET, especially if it can get through 1.25. CTE going nuts on peanuts news. Allan

To: Sergio H who wrote (2807)	8/20/2003 11:59:13 AM
From: arnold silver	Respond to of 23958

sergio, I doubled my holdings yesterday on CTE @$3.71 the stock is flying on a news report. Up 0.60. $4.35 Here is the news. CardioTech's Coronary Artery Bypass Graft Implanted in Female Diabetic 68 Years of Age -- Patient Alive and Graft Functioning Well PR Newswire - August 20, 2003 08:49 WOBURN, Mass., Aug. 20 /PRNewswire-FirstCall/ -- CardioTech International, Inc. (AMEX: CTE): CardioTech International announced today that a female diabetic 68 years of age is alive and doing well after implantation of CardioTech's CardioPass(TM) synthetic coronary artery bypass graft. On August 6th, 2003, Dr. Ivo Nesralla, Professor of Cardiac Surgery at the world renowned Instituto da Cardiologia do Rio Grande do Sul in Porto Alegre, Brazil, performed the operation. Dr. Nesralla, reports that the surgery went smoothly and the graft was easily sutured. He also reports that the patient is expected to leave the hospital and return home soon. The patient was diagnosed in very poor condition and considered a "redo" patient, as she had no useable mammary artery. Both her right coronary artery and the left descending artery were reoccluded. The doctor used a saphenous vein graft on her right coronary artery and the CardioPass patented synthetic coronary artery bypass graft on her left anterior descending (LAD) coronary artery. Dr Ivo Nesralla is Professor of Cardiac Surgery and President of the Instituto da Cardiologia do Rio Grande do Sul in Porto Alegre. The Institute is one of Brazil's leading cardiac surgery centers. Brazil is among the top three countries in the world in volume of cardiac surgery. The Institute performs almost 2,000 cardiac surgeries per year and is a dedicated hospital for the treatment of cardiology and cardiac surgery. Professor Nesralla, who is a past President of the Brazilian Society of Cardiac Surgery, commented: "I am thrilled at the patient's response to the implantation of the CardioPass. The graft is maintaining patency, operating perfectly and the patient is doing well. CardioTech's synthetic artery is truly a 21st century technology. I am hopeful that it will help extend and normalize the lives of people at risk for cardiac disease." Michael Szycher, PhD, CEO of CardioTech, commented: "This operation marks another milestone for CardioTech. This was the first adult to receive our coronary artery bypass graft. I am very grateful that Dr. Nesralla has chosen to use our technology to bring hope to patients who have no other option for revascularization of coronary arteries. The graft continues to show consistent patency and that is extremely significant and important. "